載入...
p53 immunohistochemistry in endometrial cancer: clinical and molecular correlates in the PORTEC-3 trial
Standard molecular classification of endometrial cancers (EC) is now endorsed by the WHO and identifies p53-abnormal (p53abn) EC as the subgroup with the poorest prognosis and the most likely to benefit from adjuvant chemo(radio)therapy. P53abn EC are POLE wildtype, mismatch repair proficient and sh...
Na minha lista:
| 發表在: | Mod Pathol |
|---|---|
| Main Authors: | , , , , , , , , , , , , , , , , , |
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
Nature Publishing Group US
2022
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7613653/ https://ncbi.nlm.nih.gov/pubmed/35752743 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41379-022-01102-x |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|